# EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT)

> EyePoint is a biopharmaceutical company dedicated to developing innovative therapeutics aimed at improving the lives of patients suffering from serious retinal diseases.

## About

EyePoint is a biopharmaceutical company dedicated to developing innovative therapeutics aimed at improving the lives of patients suffering from serious retinal diseases. The company focuses on sustained-release medications to treat ocular disorders.

## Key facts

- **Projects:** ["Durasert E™\n- Bioerodible version of the proven, safe Durasert® technology\n- Delivered via standard in-office IVT injection\n- No delay – reaches target tissue at therapeutic levels within hours\n- No free-floating drug – drug is delivered for at least six months before the remaining matrix fully bio-erodes\n\nEyePoint history of Durasert E™ technology – proven safety in thousands of eyes across 4 FDA- approved products, Vitrasert® (B&L), Retisert® (B&L), ILUVIEN® (ANI Pharmaceuticals) and YUTIQ® (ANI Pharmaceuticals)"]
- **Leadership:** David J. Mazzo, Ph.D. (Chairman of the Board of Directors), Göran Ando, M.D. (Board Member, Former Chairman of the Board of Novo Nordisk A/S with over 35 years of global drug development and management experience.), Scott Jones (Chief Commercial Officer, Responsible for the commercialization of DEXYCU® and YUTIQ® with significant experience in the specialty pharmaceutical industry.), Said Saim, Ph.D. (Chief Technology Officer, Over 25 years of product development experience, previously Vice President at Collegium Pharmaceutical.)

_Verified data last updated: 2026-08-07_

## Recent filings

- 2026-08-05 — financials — [eypt_2026-08-05_19-05-55.pdf](https://chat.orbiton.app/eypt/preview/110971?documentId=110971)
- 2026-08-05 — other — [eypt_2026-08-05_10-05-22.pdf](https://chat.orbiton.app/eypt/preview/109642?documentId=109642)
- 2026-07-31 — other — [eypt_2026-07-31_13-19-12.pdf](https://chat.orbiton.app/eypt/preview/106455?documentId=106455)
- 2026-07-30 — press_release — [eypt_2026-07-30_10-05-16.pdf](https://chat.orbiton.app/eypt/preview/106456?documentId=106456)
- 2026-07-28 — other — [eypt_2026-07-28_19-44-45.pdf](https://chat.orbiton.app/eypt/preview/106457?documentId=106457)
- 2026-07-22 — other — [eypt_2026-07-22_20-04-39.pdf](https://chat.orbiton.app/eypt/preview/106458?documentId=106458)
- 2026-07-22 — other — [eypt_2026-07-22_16-44-26.pdf](https://chat.orbiton.app/eypt/preview/106459?documentId=106459)
- 2026-07-21 — other — [eypt_2026-07-21_19-44-07.pdf](https://chat.orbiton.app/eypt/preview/106460?documentId=106460)

## Live AI chat

- https://chat.orbiton.app/eypt/chat
- Investor website: https://eyepoint.bio/